Melasma Clinical Trial
Official title:
Different Dermatological Approaches in Treatment of Melasma: A Split Face Randomized Clinical Trial
To compare the efficacy and safety of cryopeeling (using Liquid Nitrogen) and tranexemic acid (cyclokapron) versus chemical peeling (using TCA 20%) in treatment of melasma.
Melasma is a common, acquired, circumscribed hypermelanosis of the sun-exposed skin, It
presents as symmetric, hyperpigmented macules having irregular, serrated, and geographic
borders , The most common locations are the cheeks, upper lips, the chin and the forehead,
but other sun-exposed areas may also be occasionally involved .
Studies has indicated the role of several risk factors such as genetics, sunlight, age,
gender, hormones, pregnancy, thyroid dysfunction, cosmetics and medications .
Histologic features of melasma include an increase in the content of both epidermal and
dermal melanin, but the quantity varies with the intensity of hyperpigmentation. In addition,
most studies show no quantitative increase in melanocytes; however, the cells are enlarged
with prominent and elongated dendrites and more abundant melanosomes. Additional features of
the involved skin include solar elastosis and increased mast cells, dermal blood vessels, and
expression of vascular endothelial growth factor.
Commonly used topical agents for the treatment of melasma include hydroquinone, azelaic acid,
kojic acid, glycolic acid, salicylic acid and tretinoin. Of these treatments, hydroquinone
remains the gold standard .Second-line treatments, such as chemical peels and lasers, are
efficacious in some patients .
Chemical peeling is the application of a chemical agent to the skin, which causes the
controlled destruction of a part or of the entire epidermis with or without the dermis,
leading to exfoliation and removal of superficial lesions, followed by regeneration of new
epidermal and dermal tissues [khunger, 2008]. The mechanism of action in melasma is the
removal of unwanted melanin via controlled chemical burn of the skin .
Trichloroacetic acid has been used as a peeling agent for a long time and is still the most
effective and safest agent for medium peeling, Its depth of penetration depends on the TCA
concentration and on the preparation of the skin, specially the degreasing. Between 10% and
30% concentration is considered a superficial peel; above 30% provides a mediumādepth peel.
Cryopeeling is a technique that uses cryotherapy in a diffuse manner throughout the skin
region affected by sun damage in order to promote cell renewal and desquamation, with
possible benefits in the appearance of new lesions caused by photodamage. Up to the
investigator's knowledge, few studies were performed evaluating such technique.
Recently, trans-4-(Aminomethyl) cyclohexanecarboxylic acid, or tranexamic acid (TA), has been
proposed as a new treatment for melasma.The main mechanism of the hypopigmentant effects of
TA is due to its antiplasmin activity .In addition, TA is similar to tyrosine in a portion of
its structure, which can inhibit tyrosinase competitively .Also, Plasmin transforms the
vascular endothelial growth factor (VEGF) into a diffusing form, and histological examination
showed that TA plays an important role in the reduction of erythema and vascularities and the
number of mast cell in the dermis.Various forms of TA are used orally, topically and as a
microinjection for the treatment of melasma.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05013801 -
A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
|
N/A | |
Recruiting |
NCT06174545 -
Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma
|
N/A | |
Completed |
NCT01695356 -
Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma
|
Phase 4 | |
Recruiting |
NCT06278948 -
Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma
|
N/A | |
Not yet recruiting |
NCT05911698 -
Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.
|
N/A | |
Recruiting |
NCT05656833 -
Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma
|
N/A | |
Recruiting |
NCT04597203 -
Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial
|
N/A | |
Completed |
NCT02138539 -
Evaluation of an Herbal-Based De-Pigmenting System
|
Phase 4 | |
Recruiting |
NCT01661556 -
Clinical Trial of Hydroquinone Versus Miconazol in Melasma
|
Phase 4 | |
Completed |
NCT01001624 -
Melanil in the Treatment of Melasma
|
Phase 3 | |
Terminated |
NCT03415685 -
Lutronic PicoPlus Exploratory Clinical Trial
|
N/A | |
Recruiting |
NCT04765930 -
Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
|
N/A | |
Completed |
NCT04137263 -
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging
|
N/A | |
Recruiting |
NCT03686787 -
Oral Tranexamic Acid and Laser for Treatment of Melasma
|
Phase 4 | |
Completed |
NCT05969587 -
Cysteamine Compared to Hydroquinone in Melasma
|
Phase 3 | |
Completed |
NCT00472966 -
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
|
Phase 4 | |
Completed |
NCT00500162 -
Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma
|
Phase 4 | |
Completed |
NCT05884151 -
Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
|
Phase 1 | |
Completed |
NCT05887219 -
Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma
|
Phase 1 | |
Recruiting |
NCT03308370 -
Platelet Rich Plasma in Treatment of Melasma
|
Phase 3 |